EGFR and non-small cell lung carcinoma: In the case of NSCLC exhibiting EGFR mutations, our analysis confirms the meta-analysis of Erickson, Brastianos, and Das, that only introduction of osimertinib brought measurable progress regarding PFS and objective response rate, while effects of other substances are minimal for the case of advanced disease with brain metastases [21].